Amarin Technologies S.A. ("AMARIN" or "The Company") is engaged in the development of innovative pharmaceutical products using its proprietary topical and transdermal drug delivery technologies and know-how to offer improved formulations of established drugs. The Company is located in Buenos Aires, Argentina. Several transdermal systems containing different substances (homones, diclofenac, etc) have reached the markets. The latest products were a high permeation diclofenac gel (OXA® GEL PLUS) and a testosterone gel (Androlone® Gel), both commercilized by Laboratorios Beta SA in Argentina. A Fentanyl TDS is presently in its registration phase in Latin America and Europe while was launched by Sandoz in Argentina. Amarin has signed different development and marketing agreements with other companies in Europe and Latin America. Research and Development AMARIN performs pre-clinical and clinical studies following GLP and GCP guidelines carrying out properly designed protocols in order to evaluate safety, PK and the efficacy of the products under development. AMARIN's research and development capabilities, allow the company to perform and control all aspects of the product development process. An experienced team coordinates and manages all of the company's research, project planning and product development programs. The company performs an exhaustive background analysis of the selected agent for a transdermal formulation before beginning the developments, including the search for documentation in databases and the evaluation of the patent status. In this field, specialized personnel of the company permanently consult online services such as STN International, European Patent Office and United States Patent and Trademark Office. AMARIN possesses modern formulation and analytical laboratories, which follow GLP guidelines. The company currently designs the protocols and carries out pre-clinical as well as clinical investigations in order to evaluate the safety, pharmacokinetics and efficacy of its products. The pre-clinical studies (e.g. primary irritation, sensitization and pharmacokinetics in animals) are carried out by the clinical research section in qualified third-party facilities. Clinical trials are performed according to cGCP rules and local regulations in hospitals and other health centers. The protocols designed by its clinical research section are presented to the local Ministry of Health for authorization, after being approved by either the Institutional Review Boards (IRB) or Independent Ethics Committees (IEC). Qualified personnel closely supervise pharmacokinetic studies and clinical trials.

· AMARIN has no direct marketing force and pursues a strategy of out-licensing its products to corporate partners. The company also enters into strategic alliances that provide for the development of pharmaceutical products in return for technology funding, milestone payments, royalties and other financial arrangements. The company's business opportunities are, amongst others, focused in four main areas: (a) Finding new partners for the existing projects or, (b) Developing new products on request or, (c) Developing early stage projects to be offered to pre- determined/selected candidates or (d) Technology transfer agreements. Among the existing agreements, we can disclose those which cover products with Wyeth (U.S.A.), Merck KGaA (Germany), Zydus Cadila (India), Ranbaxy (India), Sandoz (Austria), Helm Pharmaceuticals (Germany), Laboratorios Beta S.A. (Argentina) and Mega Pharma (Uruguay).

To view this information, you must subscribe to Partneringtools.